Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology

Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.

Filter by

Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
VISION

Society for Immunotherapy of Cancer (SITC)

Nov 6
- Nov 10, 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design.
Joyce, et al.
VISION

AI Powered Drug Discovery and Manufacturing (AIDM)

Feb 27
- Feb 28, 2020
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.
Pabla, et al.
VISION

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.
QS-21 STIMULON™ Adjuvant

The Journal of Immunology

Jan 15, 1991
Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex.
Kensil, CR.
QS-21 STIMULON™ Adjuvant

The Journal of Immunology

Apr 15, 1992
Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses.
Newman, et al.
QS-21 STIMULON™ Adjuvant

Critical Reviews in Therapeutic Drug Carrier Systems

Jan 1, 1996
Saponins as Vaccine Adjuvants.
Kensil, CR.
QS-21 STIMULON™ Adjuvant

Cancer Research

Jul 1, 1995
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21.
Helling, et al.
QS-21 STIMULON™ Adjuvant

Carbohydrate Research

Jan 4, 1996
Structure of the saponin adjuvant QS-21 and its Base-Catalyzed Isomerization Product by 1H and Natural Abundance 13C NMR Spectroscopy.
Jacobsen, et al.
QS-21 STIMULON™ Adjuvant

New England Journal of Medicine

Jan 9, 1997
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute, et al.
QS-21 STIMULON™ Adjuvant

Journal of Virology

Jun 1, 1998
Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated With QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes.
Sasaki, et al.